Sean Ronnekleiv-Kelly, MD, FACS

Assistant Professor

  • Endowed Professor, Ronald E. and Patricia A. Kissinger Surgical Oncology Research Professorship 
  • Division of Surgical Oncology

ronnekleiv-kelly@surgery.wisc.edu
Clinic: (608) 263-7502

  • Administrative Assistant: (608) 262-2025

600 Highland Ave
BX 7375
K4/757 CSC
Madison, WI 53792

Education

  • MD, University of Colorado School of Medicine, 2008
  • General Surgery Residency, University of Wisconsin School of Medicine and Public Health, 2015
  • Complex General Surgical Oncology Fellowship, Johns Hopkins Hospital, 2017

Clinical Specialties

Certified by the American Board of Surgery in General Surgery and specializes in malignant disease of the pancreas, liver, gallbladder and biliary tree, stomach and small intestine, neuroendocrine tumors and retroperitoneal sarcoma.

Research Interests

Principal research interest is pancreatic cancer. My lab focuses on formation and progression of pancreatic cancer as well as understanding communication within the tumor microenvironment.

Recent Publications

  • Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative.
    Wiseman JT, Ethun CG, Cloyd JM, Shelby R, Suarez-Kelly L, Tran T, Poultsides G, Mogal H, Clarke C, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick B, Fields R, Walle KV, Ronnekleiv-Kelly S, Howard JH, Cardona K, Grignol V
    J Surg Oncol 2020 Jul 21;
    [PubMed ID: 32696475]

  • Early vs Late Readmissions in Pancreaticoduodenectomy Patients: Recognizing Comprehensive Episodic Cost to Help Guide Bundled Payment Plans and Hospital Resource Allocation.
    Acher AW, Barrett JR, Schwartz PB, Stahl C, Aiken T, Ronnekleiv-Kelly S, Minter RM, Leverson G, Weber S, Abbott DE
    J. Gastrointest. Surg. 2020 Jul 15;
    [PubMed ID: 32671797]

  • Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.
    Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M
    J Surg Oncol 2020 Jul 05;
    [PubMed ID: 32627199]

  • What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?
    Schwartz PB, Stahl CC, Vande Walle KA, Pokrzywa CJ, Cherney Stafford LM, Aiken T, Barrett J, Acher AW, Leverson G, Ronnekleiv-Kelly S, Weber SM, Abbott DE
    Ann. Surg. Oncol. 2020 May 15;
    [PubMed ID: 32415351]

  • The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC.
    Turgeon MK, Gamboa AC, Lee RM, Zaidi MY, Kimbrough C, Grotz T, Fournier K, Powers B, Dineen S, Veerapong J, Clarke C, Mogal H, Patel SH, Lambert L, Ronnekleiv-Kelly S, Raoof M, Fackche N, Greer JB, Staley CA, Cloyd JM, Maithel SK, Winer JH
    Ann. Surg. Oncol. 2020 May 06;
    [PubMed ID: 32378087]

All Publications on PubMed